StockData
Medifast Inc logo

Medifast Inc (MED) stock

MEDNYSEMiscellaneous Food Preparations & Kindred ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 10/3057% below fair value
$12.19−0.35 (-2.79%)

Close on Nov 17, 2026Market cap $136.32MP/E –Yield 0.00%

Earnings

Medifast's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 16, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$72.00M
-19.5% on a year earlier
non-GAAP adjusted loss per diluted share, Q3 FY2026
$0.19
-$0.21 a year earlier
Latest guidance
Issued
Oct 26, 2026 · 7 items

Quarterly results

Revenue and earnings per share from each of Medifast's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 16, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 26, 2026before the open$72.00M-19.5%$1.57$0.19Release
Q2 FY2026ended Jun 30, 2026Aug 3, 2026during market hours$76.40M-27.7%-$0.28–Release
Q1 FY2026ended Mar 31, 2026May 4, 2026during market hours$76.00M-34.3%-$0.19–Release
Q4 FY2025ended Dec 31, 2025Feb 17, 2026during market hours$75.10M-36.9%-$1.65–Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025during market hours$89.40M-36.2%-$0.21–Release
Q2 FY2025ended Jun 30, 2025Aug 4, 2025during market hours$105.60M-37.4%$0.22–Release
Q1 FY2025ended Mar 31, 2025Apr 28, 2025during market hours$115.70M-33.8%-$0.07–Release
Q4 FY2024ended Dec 31, 2024Feb 18, 2025during market hours$119.00M-37.7%$0.07$0.10Release
Q3 FY2024ended Sep 30, 2024Nov 4, 2024during market hours$140.20M-40.6%$0.10$0.35Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024during market hours$168.60M-43.1%-$0.75$0.92Release
Q1 FY2024ended Mar 31, 2024Apr 29, 2024during market hours$174.70M-49.9%$0.76$0.66Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Medifast's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueQ4 FY2026$55.00M – $75.00M–NewOct 26, 2026
Adjusted EBITDA excluding interest incomenon-GAAPQ4 FY2026$2.00M – $6.00M–NewOct 26, 2026
income per shareGAAPQ4 FY2026$0.00 – $0.25–NewOct 26, 2026
revenueFY2026$280.00M – $300.00M–NewOct 26, 2026
revenueFY2026$270.00M – $300.00M$270.00M – $300.00MReaffirmedAug 3, 2026
Adjusted EBITDA excluding interest incomenon-GAAPFY2026$10.00M – $14.00M–NewOct 26, 2026
loss per shareGAAPFY2026$1.80 – $2.05–NewOct 26, 2026
loss per shareFY2026-$1.75 – -$0.25-$2.75 – -$1.55RaisedAug 3, 2026
loss per sharenon-GAAPFY2026$0.45 – $0.70–NewOct 26, 2026

Guidance vs results

The last range Medifast gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026loss per share-$0.65 – -$0.15$0.19Above range
Q3 FY2026Revenue$60.00M – $80.00M$72.00MWithin range
Q2 FY2026EPS (GAAP)-$1.00 – -$0.50-$0.28Above range
Q2 FY2026Revenue$60.00M – $80.00M$76.40MWithin range
Q1 FY2026EPS (GAAP)-$0.70 – -$0.15-$0.19Within range
Q1 FY2026Revenue$65.00M – $80.00M$76.00MWithin range
Q4 FY2025EPS (GAAP)-$1.25 – -$0.70-$1.65Below range
Q4 FY2025Revenue$65.00M – $80.00M$75.10MWithin range
Q3 FY2025EPS (GAAP)-$0.60 – $0.00-$0.21Within range
Q3 FY2025Revenue$70.00M – $90.00M$89.40MWithin range
Q2 FY2025Revenue$85.00M – $105.00M$105.60MAbove range
Q1 FY2025Revenue$100.00M – $120.00M$115.70MWithin range

Guidance history

Every forecast Medifast put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 26, 2026Adjusted EBITDA excluding interest incomeQ4 FY2026$2.00M – $6.00MNew
Oct 26, 2026Adjusted EBITDA excluding interest incomeFY2026$10.00M – $14.00MNew
Oct 26, 2026loss per shareFY2026$0.45 – $0.70New
Oct 26, 2026income per shareQ4 FY2026$0.00 – $0.25New
Oct 26, 2026loss per shareFY2026$1.80 – $2.05New
Oct 26, 2026revenueQ4 FY2026$55.00M – $75.00MNew
Oct 26, 2026revenueFY2026$280.00M – $300.00MNew
Aug 3, 2026loss per shareQ3 FY2026-$0.65 – -$0.15New
Aug 3, 2026loss per shareFY2026-$1.75 – -$0.25Raised
Aug 3, 2026revenueFY2026$270.00M – $300.00MReaffirmed
Aug 3, 2026revenueQ3 FY2026$60.00M – $80.00MNew
May 4, 2026loss per shareFY2026-$2.75 – -$1.55Reaffirmed
May 4, 2026loss per shareQ2 FY2026-$1.00 – -$0.50New
May 4, 2026revenueFY2026$270.00M – $300.00MReaffirmed
May 4, 2026revenueQ2 FY2026$60.00M – $80.00MNew
Feb 17, 2026loss per shareFY2026-$2.75 – -$1.55New
Feb 17, 2026loss per shareQ1 FY2026-$0.70 – -$0.15New
Feb 17, 2026revenueFY2026$270.00M – $300.00MNew
Feb 17, 2026revenueQ1 FY2026$65.00M – $80.00MNew
Nov 3, 2025diluted loss per shareQ4 FY2025-$1.25 – -$0.70New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Medifast filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Update
  5. Update
  6. Results
  7. Update
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?